Unbiased screen turns up genes expressed in immune cells, both inside and outside the CNS.
Trials enrolling people all at the same Braak stage would need fewer participants to show a drug effect, according to a new analysis.
Study of disease subtypes boosts case for NfL as predictor of rapidly progressing ALS.
Combining PET with MRI reveals near-complete overlap of tau tracer uptake with cortical atrophy and clinical features in typical and atypical AD.
NIH funds a five-year project to validate biomarkers for clinical trials.
ALS patients eliminate more p75 neurotrophin receptor than do healthy controls. P75 urine levels rise as disease worsens.
A simple blood draw may help distinguish garden-variety PD from other, less common parkinsonian disorders early in disease.
Branch out, scientists at Alzheimer’s Research UK conference say. Go after tau, glial activation, lipids, in a systematic way. Understand how these pathways connect to the amyloid hypothesis.
Convened by ARUK to learn from the antibody’s billion-dollar bust, industry and academic leaders declare insufficient CNS target engagement, say peripheral sink did not work, and brainstorm how to move forward.
Diurnal variations disappear as less Aβ42 reaches cerebrospinal fluid. Findings may improve timing of daily amyloid treatments.
Methods that trawl body fluids for amyloidogenic proteins are getting more sensitive and specific, and scientists are expanding the repertoire of oligomers they can detect.
At CTAD, tau-PET data from people in different stages of various neurodegenerative diseases highlighted both commonalities and peculiarities.
Cognitively normal people who harbor plaques in their brains are more likely to report feelings of isolation.
Researchers at SfN 2016 reported that oligomeric and exosomal forms in plasma predict AD as early as a decade prior to symptoms.
Where does TREM2-dependent microglial activity fit into the staging diagram of Alzheimer’s disease?